Introduction
Chronic cold agglutinin disease (CCAD)1 is an autoimmune hemolytic anemia characterized by the production of a monoclonal IgM antibody (almost invariably IgM kappa) which reacts optimally at temperatures below 370C with determinants of the I-antigen system of human erythrocytes (1, 2) . The pathogenesis of the disease has been enigmatic. Whether the chronic production of the antibody is the manifestation of an immunoregulatory defect, a neoplastic process, or a physiological response to a stimulus has never been clearly defined. Since antigenic determinants of the I-system are associated with the carbohydrate moiety of the major erythrocyte sialoglycoprotein, glycophorin-a2 (1, 2), we compared the glycoproteins of CCAD erythrocytes with those of normal erythrocytes to determine if abnormal membrane constituents might provide 1. Abbreviations used in this paper: 5P(8)BS-PE, phosphate-buffered saline containing 150 mM sodium chloride, 5 mM sodium phosphate, 1 mM PMSF, and I mM EDTA, pH 8.0; 5P(8)-PE, 5 mM sodium phosphate containing I mM PMSF and I mM EDTA, pH 8.0; C, complement; CCAD, chronic cold agglutinin disease; CoF, cobra venom factor; CoFBb, activated cobra venom factor complexes; CR1, human erythrocyte receptor for C3b; E*C3, radiolabeled erythrocytes bearing nonspecifically bound C3; E*C3b, radiolabeled erythrocytes bearing C3b; Ep*C3*, erythrocytes bearing nonspecifically bound C3 subsequently radiolabeled using NaIO4 and NaB3H4; Ep*C3b*, erythrocytes bearing C3b subsequently radiolabeled using NaIO4 and NaB3H4; EC3*, erythrocytes bearing nonspecifically bound radiolabeled C3; the stimulus for antibody production. These investigations demonstrated an abnormal membrane glycoprotein (GPc.) associated with the CCAD erythrocytes. In addition, CCAD erythrocytes were found to bind 7-27 times more fluid-phase activated complement (C)3b than normal erythrocytes, and this greater efficiency of binding of nascent C3b appeared to be a consequence of the presence of GP,. The acquisition of GP<,,, however, is an epiphenomenon resulting from the interactions of the IgM cold agglutinin and complement with erythrocyte membrane glycoproteins. This appears to be the first instance in which antibody and complement reacting with cell surface constituents has been demonstrated to induce changes in the intrinsic biochemical/biophysical properties of the membrane, and thereby, to render subsequent interactions with complement aberrant. Because these changes occur in vivo, they may be implicated in the pathophysiological manifestations of CCAD.
Methods
Buffers. The following buffers were employed: Veronal-buffered saline, pH 7.5 (VBS); VBS containing 0.1% gelatin (GVB); GVB containing 5 mM magnesium (GVB+); GVB containing 0.15 mM calcium and 0.5 mM magnesium (GVB++); GVB containing 1% bovine serum albumin (BSA) (Sigma Chemical Co., St. Louis, MO); GVB containing 15 mM EDTA (Sigma Chemical Co.) (GVB-EDTA); 3.5 mM veronal buffer containing 10 mM sodium chloride, 1% BSA, 3.5% dextrose, 0.2% sodium azide, and 20 mM EDTA; Alsever's solution (3); phosphate-buffered saline (PBS) containing 150 mM sodium chloride and 10 mM sodium phosphate, pH 7.4 (PBS); PBS containing 150 mM sodium chloride, 5 Human erythrocytes, plasma, and serum. Erythrocytes from normal donors or from patients with CCAD were drawn under sterile conditions using EDTA as an anticoagulant. The erythrocytes were pelleted and the plasma was aspirated and frozen at -90°C. Then, the erythrocytes were washed in GVB-EDTA which had been prewarmed to 37°C. After the third wash, the supernate was aspirated as completely as possible and the erythrocytes were stored at 4°C in an equal volume of Alsever's solution. Serum from normal donors or from patients with CCAD was obtained by allowing blood to clot at 37°C. After clot retraction occurred, the supernate was recovered and frozen at -90°C. Cold agglutinin titers. Agglutination tests to determine I-antigen specificity were performed by simultaneously incubating 50 ul of O+ adult erythrocytes (2.2 X 108/ml) or 50 ul of O+ fetal erythrocytes (cord cells) (2.2 X 108/ml) with twofold falling dilutions of an equal volume of EDTA-chelated plasma for 4 h at 4°C. Agglutination was scored from 4+ (complete) to trace (barely visible to the unaided eye). The titer is the greatest dilution showing trace agglutination.
Purification of cold agglutinin. The antibodies were purified by sequential adsorption and elution from normal erythrocytes as previously described (4) . The immunoglobulin class of the purified antibody was determined using immunoelectrophoresis and antibodies specific for IgG, IgM, and kappa and lambda light chains.
Complement components. C3, factor B, and cobra venom factor (CoF) (5) were purified to apparent homogeneity as assessed by sodium dodecyl-sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (3) . Functionally purified factor D was prepared as previously described (3).
Antibodies. Monoclonal antibodies specific for C3dg (6-9) and the human erythrocyte receptor for C3b (CRI) (10) were the kind gifts of Dr. Gordon D. Ross (University of North Carolina, Chapel Hill, NC).
These antibodies were purified from the ascites using 5% caprylic acid (Sigma Chemical Co.) (9) . Monoclonal antibodies against C3c and human IgG were purchased as ascites fluid from Bethesda Research Laboratories (Gaithersberg, MD). The anti-C3c was purified as described (3) , while the anti-IgG was purified using 5% caprylic acid (9) . Affinitypurified goat anti-human IgM was purchased from Tago, Inc. (Burlingame, CA). The anti-glycophorin antibody is a murine monoclonal antibody which recognizes an epitope common to all glycophorin species (11) . The 125I-labeled affinity-purified sheep F(ab`)2 anti-mouse, and anti-rat IgG were purchased from Amersham Corp. (Arlington Heights, IL).
Radiolabeling with 125j. C3, anti-C3c, anti-C3dg, anti-CRI, antiIgG, and anti-IgM were trace labeled with 125j as Nal (Amersham Corp.) using IODO-GEN (Pierce Chemical Co., Rockford, IL) as previously described (5) .
Surface labeling of CCAD and normal erythrocytes with 125j was accomplished using IODO-GEN exactly as described by Markwell and Fox (12) .
Determination ofcell-bound C3c, C3dg, CRI, IgG, and IgM. The amount of radiolabeled antibody used in each of the assay systems was in excess as determined by saturation binding studies.
Using '25I-anti-C3c (5), '25I-anti-C3dg (8) , and '23I-anti-CRI (10), the amount of erythrocyte bound C3c, C3dg, and the number of erythrocyte CR1 sites were determined as previously described.
To assess cell-bound IgG, erythrocytes were washed three times in To determine cell-bound IgM, erythrocytes were washed three times in GVB-EDTA and resuspended to I X 109/ml. In quintuplicate, 10 Ml of cells were incubated with 10 Ml of '25I-anti-IgM (20 pg/ml) in a final volume of 50 Ml of GVB-EDTA. To control for nonspecific binding of the radiolabeled ligand, the above experiment was performed simultaneously in the presence of a 50 M excess of unlabeled antiIgM. After incubation for 30 min at 37°C, a 40-Ml aliquot was aspirated from each reaction mixture and bound from unbound ligand was separated as previously described (5) . The amount of radiolabeled ligand bound to each cell-type in the presence and absence of unlabeled ligand was determined, and the mean and standard deviation of each set of quintuplicates was calculated. If there was no statistically significant difference (P > 0.1) between the amount of '25I-anti-IgM bound in the absence of unlabeled anti-IgM as compared with binding in the presence of unlabeled ligand, then the cell-bound IgM was designated as negative.
SDS-PAGE ofCCAD and normal erythrocytes labeled with sodium meta-periodate (NaIO4/tritiated sodium borohydride (NaBHd). These procedures were performed using the methods which are described in detail in reference 13.
Efficiency of binding offluid-phase activated C3b to normal and CCAD erythrocytes. Normal and CCAD erythrocytes were washed three times in GVB-EDTA and resuspended to 1 X 109/ml. Activated cobra venom factor complexes (CoFBb) were prepared by incubating 300 ,d of cobra venom factor (CoF) (1.02 mg/ml), 300 ,ul of factor B ( were incubated for 30 min at 37°C, and then washed three times in 5P(8)BS-PE. Ghost cells were prepared as previously described (13) . Specific activity was determined, and the ghost were subjected to SDS-PAGE. After staining and destaining, autoradiographs were prepared. Electrophoresis in the second dimension, after treatment of the tracks of interest with hydroxylamine, was performed as previously described (13) .
Preparation ofCCAD erythrocytes bearing C3b subsequently labeled with NaIO4/NaB3H4. 500 ,ul of packed CCAD erythrocytes which had been washed three times in GVB-EDTA were incubated with 290 JAl of CoFBb complexes and 200 ,ul of C3 (10 mg/ml) for 30 min at 370C (controls were CCAD erythrocytes incubated with C3 in the absence of CoFBb complexes). The cells were washed once in GVB-EDTA and twice in PBS and radiolabeled using NaIO4/NaB3H4 as previously described (13 Preparation ofnormal erythrocytes exposed to CCAD serum, purified antibody, and purified antibody plus autologous serum. Erythrocytes from a normal O+ donor were washed three times in GVB++. To one aliquot of I ml of packed cells was added 3 ml of CCAD serum. To another aliquot was added 3 ml of serum from a normal donor of the same blood type as the patient with CCAD (A'). The reaction mixtures were incubated for 30 min at 30°C, then for 60 min at 37°C. The cells were washed three times in GVB-EDTA (which had been prewarmed to 37°C) and resuspended to 4 ml in the same buffer. 2 ml were aspirated from each set for determination of cell-bound IgM, IgG, C3c, C3dg, CRI sites/cell, and efficiency of binding of fluidphase-activated C3. The remaining 2 ml were radiolabeled using NaIO4/NaB3H4 as described ( 13) . The radiolabeled ghost proteins were then electrophoresed and fluorographs were prepared (13) .
By titration experiments, it was determined that on a volume basis the purified anti-I was 10-fold more potent than CCAD serum at producing agglutination. Therefore, for experiments involving purified antibody, the IgM anti-I was diluted 1:10 in order to simulate CCAD serum conditions. To I ml of packed normal O+ erythrocytes washed in GVB++, 300 Ml of purified cold agglutinin (3.3 mg/ml) diluted to 3 ml in GVB++ was added. Controls for these experiments were erythrocytes incubated with 3 ml of GVB++. The format for the remainder of the experiment was the same as that described above for normal erythrocytes plus CCAD serum.
For incubation of normal autologous serum or EDTA-serum with anti-I plus normal erythrocytes, cells were washed three times in either GVB++ or GVB-EDTA. To I ml of the erythrocytes washed in GVB++, 300 ul of anti-I plus 2.7 ml of autologous serum was added. To 1 ml of packed erythrocytes washed in GVB-EDTA was added 300 UI of anti-I plus 2.7 ml of EDTA-chelated serum. The remainder of the format for the experiment was the same as that described above for normal erythrocytes plus CCAD serum.
Protein concentration. The protein concentration of the radiolabeled anti-C3dg, anti-CRI, anti-IgM, anti-3c, and anti-IgG was determined using an Elea'l at 280 nm of 1.4. Other protein determinations were made using Bio-Rad protein assay (Bio-Rad Laboratories) with bovine IgG as the standard.
Statistical methods. Group data were compared by Student's paired t test.
Results
Patient profiles. CCAD is a disease of older patients (Table I) (1, 2). None of the patients included in this study had evidence of an associated neoplastic process. Patient R.H. was undergoing an accelerated hemolytic phase of his disease induced by events associated with surgery. As a result, he had been transferred to the Durham Veterans Administration Hospital, NC. He had been transfused with one unit of packed erythrocytes 12 d prior to initiation of the studies reported here. He had also been on chronic low-dose steroid therapy since the CCAD was originally diagnosed in 1969. The steroids were tapered and discontinued while he was an outpatient. None of the other three patients had been transfused within the preceding year. Patients P.T. and A.B. were being treated with intermittent chlorambucil while patient C.P. was on no medications. All patients, except P.T., had associated acrocyanosis and/or coldrelated vaso-occlusive phenomena; patient C.P. was the most severely affected. The cold-reacting antibody in each case was defined as anti-I (as opposed to anti-i) since it reacted more strongly with adult erythrocytes than with fetal erythrocytes (Table I) . As is almost invariably the case in CCAD with anti-I specificity, the IgM cold agglutinins had kappa light chains (Table I) , suggesting a monoclonal origin for the disease (2). The antibody titer was extremely variable among the four patients (Table I) .
SDS-PAGE of radiolabeled CCAD erythrocytes. To determine if the erythrocytes of CCAD are abnormal, the terminal sialic acid residues of the membrane glycoproteins were oxidized with sodium meta-periodate, then labeled by reduction with tritiated sodium borohydride. The membrane proteins were then subjected to SDS-PAGE. There was no difference in the Coomassie staining pattern for CCAD erythrocytes compared with normal erythrocytes (Fig. 1) . Fluorographs, however, revealed the presence of a band (GP,,,) of Mr = 126,000 on the erythrocytes of the four patients with CCAD which was not present on normal erythrocytes (Fig. 1 (Table  II) . This is consistent with the findings reported by Lachmann et al. (17) . Using the monoclonal antibody to CR1, we have observed that CR1 sites are low on erythrocytes from patients with IgGmediated warm antibody hemolytic anemia who have C3dg present on their cells (18) . We, therefore, used this antibody to determine CR1 sites on CCAD erythrocytes. The erythrocytes from all four patients had low numbers of CR1 sites with the erythrocytes of three of the four patients having extremely low values (Table II) .
Electrophoretic blotting of normal and CCAD erythrocyte membrane proteins with subsequent immune fixation with monoclonal anti-glycophorin and anti-C3dg. To determine if Figure 1 . SDS-PAGE of normal and CCAD erythrocyte membrane proteins. The terminal sialic acid residues of membrane glycoproteins were radiolabeled using NaIO4/NaB3H4, then subjected to SDS-PAGE. The gels were stained with Coomassie Blue and fluorographs were subsequently prepared. 25 ,g of erythrocyte membrane proteins were loaded onto each track. Lanes 1-3 are Coomassie-stained tracks. Lane 1, molecular weight markers; lane 2, erythrocyte membrane proteins from normal control; lane 3, erythrocyte membrane proteins from patient P.T. Lanes 4-1 are tracks from fluorographs. The glycophorins are a composite part of GP,,, normal and CCAD erythrocyte proteins were subjected to SDS-PAGE followed by immunoblotting and immunofixation using a monoclonal antibody which recognizes an epitope expressed by all species of glycophorin molecules including the homo and heterodimers (Fig. 2 A, lane 1) (1 1) . The antibody also interacts with normal erythrocytes membrane proteins at positions not heretofore associated with glycophorins ( Fig. 2 A, arrows 4 and 5). While direct proof is lacking, it seems likely that these proteins represent previously unrecognized homo or heteropolymers of glycophorin. For the CCAD erythrocytes, there is greater radioactivity at the position indicated by arrow 4 ( Fig. 2 A,  lanes 2 and 4) . In addition, there are three other radioactive bands of higher molecular weight present on the CCAD erythrocytes ( Fig. 2 A, arrows 1, 2, and 3 ). There is no obvious difference in the pattern of radioactivity for the erythrocytes membranes treated with hydroxylamine compared with their untreated counterparts (Fig. 2 A, lane 1 Neg., negative. * Cell-bound IgM was determined using a '25I-labeled affinity-purified goat antihuman IgM. Negative means that there was no statistically significant difference (Fig. 2  B, lanes 1 and 3) . For the CCAD erythrocytes, radioactive bands were seen in positions corresponding to arrows 1-4 in Fig. 2 A (Fig. 2 B, lane 2) . When the CCAD erythrocytes were treated with hydroxylamine, a prominent band of molecular weight 36.5 kD appeared (Fig. 2 B, lane 4) .
The data represented in Fig. 2, A although the stoichiometric relationship between the two proteins and the exact subunit composition of the complexes cannot be determined from these experiments. GlycophorinC3dg complexes of higher molecular weight are also observed for the CCAD erythrocytes. Indeed, the most intensely radioactive bands seen in the immunoblot developed with the antiC3dg (Fig. 2 B) are these higher molecular weight complexes (Fig. 2 B, arrows 1 is due to a higher ratio of C3dg to glycophorin molecules or to conformational differences of the C3dg molecules within these complexes which makes the C3dg more accessible to interaction with the antibody is uncertain. The appearance of the 36.5 kD band after treatment of CCAD erythrocytes with hydroxylamine ( Fig. 2 B, lane 4) is consistent with release of C3dg which had been bound to a membrane constituent via an hydroxylamine-sensitive ester bond (14, 15, 19, 20) . (In our experience, the molecular weights calculated using data from immunoblotting experiments is consistently 15-20% lower than that calculated using relative mobility data from SDS-PAGE systems alone. Thus, the value of 36.5 kD for the molecular weight of the C3dg, derived from our immunoblotting experiments, is not inconsistent with the previously published value of 41 kD [7] ). It appears that only a very minor fraction of the cell-bound C3dg was released from the CCAD erythrocytes by treatment with NH2OH. This is consistent with the majority of the bonding being mediated by hydroxylamine-resistant imidoester bonds (14, 15, 19, 20) .
Efficiency of binding of nascent C3b to normal and CCAD erythrocytes. Previous studies from this laboratory have dem- 20 ,000 H onstrated that abnormalities in glycophorin influence the functional activity of complement (13) . Because GP,, is composed, at least in part, of glycophorin, it seemed possible that its presence on CCAD erythrocytes might induce aberrent interaction with complement. We, therefore, compared the efficiency of binding of nascent C3b (activated in the fluid-phase by CoFBb) with CCAD and normal erythrocytes (Fig. 3) Fig. 4 . In contrast, the specific activity of the CCAD EC3* was <4% of that of the CCAD EC3b*.
The pattern of binding of '25I-C3b to CCAD erythrocytes is clearly different than that of binding to normal EC3b* (Fig.  4 , lane 4 vs. lane 2). For normal EC3b*, the majority of the bound '25I-C3b is part of a complex of M, = 255,000 (Fig. 4 , lane 2) (this pattern of binding of fluid-phase activated 125I- C3b to normal erythrocytes is the same as that seen when 1251I
C3b is activated by the cell-bound nephritic factor-stabilized alternative pathway convertase [13] ). In addition to the 255 kD band seen with the normal EC3b*, the CCAD EC3b* have two higher molecular weight '25I-C3ba-E complexes (Fig. 4 , lane 4). When the CCAD EC3b* were treated with hydroxylamine, all of the '251I-C3ba-chain was released from the higher molecular weight complexes, suggesting that the a-chain had been covalently bound to CCAD erythrocytes membrane constituents via an ester bond (Fig. 4, lane 5) . This contrasts sharply with results of the experiment depicted in Fig. 2 B in which only a very small portion of the cell-bound C3dg was susceptible to release by treatment with hydroxylamine ( Fig. 2  B, lane 4) . There was no activation of C3 in the absence of CoFBb complexes (Fig. 4, lanes 6 and 8) and the amount of C3 activated by the CoFBb complexes in the presence of normal erythrocytes was the same as that in the presence of CCAD erythrocytes [defined by ratio of '25I-C3:'25I-C3b (Fig. 4 , lane 7 compared with lane 9)]. Binding ofC3b to radiolabeled CCAD erythrocytes. CCAD erythrocytes were first radiolabeled with '25I and then exposed to unlabeled C3 in the presence (E*C3b) or absence (E*C3) of CoFBb complexes. Autoradiographs of the radiolabeled membrane proteins after SDS-PAGE demonstrated the appearance of two high molecular weight bands for the CCAD E*C3b (Fig. 5, lane 1) . These bands correspond in electrophoretic mobility to the two higher molecular weight bands seen for the CCAD EC3b* (Fig. 4, lane 4) . Unlabeled CCAD erythrocytes were also exposed to unlabeled C3 in the presence (E;C3b*) or absence (Ep*C3*) of CoFBb complexes then radiolabeled using periodate and titrated borohydride. In this experiment, then, there is potential for simultaneous labeling of both the membrane glycoproteins and cell-bound C3b. The higher molecular weight bands seen with the E*C3b (Fig. 5 , lane 1) are also seen with the E4C3b* (Fig. 5, lane 4) . In addition, the 255 kD band seen with the CCAD EC3b* (Fig.  4, lane 4) is also faintly visible. This experiment also shows radiolabeling of the (B-chain of C3 (Fig. 5, lanes 3 and 4) demonstrating that the carbohydrate moiety of this chain has sialic acid constituents, and that these residues are accessible to oxidation by periodate.
Both radiolabeling techniques label GP,,, although the intensity of labeling is relatively poor in the 1251 system (Fig.   5 ), suggesting that the conformation of the GP;,, is such that its tyrosine residues are not readily available for incorporation of the 1251I. For both the CCAD E*C3b and the EpC3b*, there appears to be less radioactivity of GP,, than for their control counterparts (E*C3 and EpC3*, respectively) (Fig. 5, lane 1 vs. lane 2, and lane 4 vs. lane 3), suggesting that C3b is binding to GPa, and thereby displacing it from its normal position.
Two dimensional gel electrophoresis of CCAD E*C3b. It seemed likely that the difference in the efficiency and pattern of binding of fluid-phase activated C3b to CCAD erythrocytes related to the presence of the GP<,, on these cells. To determine if nascent C3b were binding to GP,,, CCAD E*C3 and E*C3b were subjected to SDS-PAGE in the first dimension. The tracks were then isolated and treated with NH20H. Following electrophoresis in the second dimension, autoradiographs were prepared.
After release of the C3ba chain by NH20H, the membrane component of the E*-C3ba-complex was seen to migrate in the same horizontal planes as the glycophorin-a monomer and dimer (Fig. 6 A, arrows 1 and 2 ). Corresponding areas of exposure were not seen on the film of the NH20H-treated E*C3 (Fig. 6 B) . However, one cannot conclude from these experiments that nascent C3b is not binding to GPC,, since GPc. itself consists predominately of glycophorin-a (Fig. 6 A and B, arrows 3 and 4). The immunoblotting experiments described above suggested that C3dg is also a composite part of the GP,. However, no constituents of GP,, other than the glycophorin-a monomer and dimer are visualized in the autoradiographs of the two-dimensional gels. This suggests that either the ratio of C3dg to glycophorin-a in the GP,, is so low Radiolabeled CCAD erythrocytes bearing C3b. CCAD erythrocytes were radiolabeled with '251 using the IODO-GEN method then exposed to unlabeled C3 in the presence (E*C3b) or absence (E*C3) of activated CoF complexes. Ghosts were prepared, solubilized in SDS, and electrophoresed under reducing conditions. After staining and destaining, autoradiographs were prepared: lane 1, CCAD E*C3b; lane 2, CCAD E*C3. C3ba-E* denotes a complex of C3ba-chain covalently bound to a radiolabeled membrane constituent. GP,,. is the abnormal membrane glycoprotein associated with CCAD. Band 3 is a normal integral membrane glycoprotein which is radiolabeled when this iodination procedure is employed. The Greek symbols denote the glycophorin monomers and homo-and heterodimers. Lanes 3 and 4 are tracks from the fluorograph of CCAD erythrocytes which were exposed to unlabeled C3 in the presence (E*p3b*) and absence (Ep*C3*) of CoFBb, then radiolabeled using periodate and tritiated borohydride. After solubilization in SDS, the membrane proteins were subjected to SDS-PAGE. The gels were stained and destained, and fluorographs were prepared: lane 3, CCAD E*pC3*; lane 4, CCAD E*pC3b*. C3b*a-E*p denotes a complex of C3b a-chain covalently bound to an erythrocyte membrane constituent. Because the cells were labeled after binding of C3b to the membrane surface, there is potential for radiolabeling both the C3b a-chain component and the erythrocyte membrane component of the complex. GP,, is the abnormal membrane protein associated with CCAD erythrocytes. The Greek symbols denote the glycophorin monomers and homodimers and heterodimers. C3B* denotes the position of the uncomplexed ,-chain of C3b which is radiolabeled.
that the labeled complexes containing C3dg are not seen under these conditions of exposure, or that the presence of the C3dg within the complex is such that it induces conformational changes which inhibit radiolabeling of the constituents.
The glycophorin-a monomer and homodimer interconvert in SDS-PAGE systems even in the absence of treatment with NH20H or reducing agents (13) . Apparently, the glycophorin-5 monomer and homodimer and the glycophorin-heterodimer are also involved in this interconversion phenomenon accounting for the exposed areas which are off-diagonal in the same vertical planes as these glycoproteins when on-diagonal (Fig.  6, A (Fig. 7 B) .
Normal erythrocytes which had been incubated with CCAD serum were also assayed for the presence of cell-bound IgM, IgG, C3c, and C3dg, and for CR1 sites (Table IV) . Essentially all cell-bound C3b was converted to C3dg during the incubation period, but neither this conversion process nor the presence of large amounts of C3dg effected a reduction in the number of CR1 sites (Table IV) .
These experiments demonstrate that the interactions of the cold agglutinin and complement with erythrocyte membrane glycoproteins produce the GP, and the associated greater efficiency of binding of nascent C3b.
Discussion
The studies reported here demonstrate that in vivo and in vitro interactions of IgM cold-reacting antibodies and complement with the erythrocyte membrane induce changes in cellsurface glycoproteins, and that these alterations modify subsequent interaction with complement.
The abnormal membrane protein associated with CCAD (GP.) appears to consist primarily of glycophorin-a and C3dg (Fig. 2, A and B) . Because antigenic determinants of the I system are present on glycophorin molecules (1, 2) , it would appear that GPc. formation is the result of activation of complement by anti-I with subsequent binding of C3b (which is ultimately degraded to C3dg [6] ) to glycophorin-a. However, the results of the two-dimensional gel experiments (Fig. 6, A and B) which show dissociation of GPc. (possibly including components of the cascade beyond C3) with glycophorin-a being responsible for the biophysical changes which effect the formation of the polymer. Studies using sera ' deficient in particular complement components are underway to determine which elements of the complement system are Figure 6 . Autoradiograph of two-dimensional gel analysis of the CCAD E*C3b (A) and E*C3 (B) membrane proteins described under Fig. 4 , lanes 1 and 2. After electrophoresis of the proteins in the first dimension, the tracks were isolated, treated with hydroxylamine to release the ester bound C3b, and electrophoresed in the second dimension under reducing conditions. (A) E*C3b. An autoradiograph of the track after electrophoresis in the first dimension is placed above and beside the film to define the vertical and horizontal planes of the radiolabeled membrane proteins. Table II. required for GP,, formation. We are also investigating the ability of IgG antibodies (both cold-and warm-reacting) to induce membrane changes similar to those seen with the IgM anti-I.
To understand the etiology of the greater efficiency of binding of nascent C3b to CCAD erythrocytes, it is necessary to examine the biochemistry of both glycophorin-a and C3 activation and binding (13) . Glycophorin-a is the major erythrocyte sialoglycoprotein (there are -1 X 106 copies/cell). The molecule is 60% carbohydrate by weight with 9 of the first 15 amino acids being O-glycosidically linked with oligosaccharides. C3 is composed of an alpha (127,000 D) and a beta (75,000 D) chain. Upon enzymatic activation, a 10,000 D fragment (C3a) is cleaved from the a-chain. This alters the conformation of the molecule such that an internal thioester bond within the a-chain is exposed. This exposed but intact thioester bond constitutes the labile-binding site of C3b. It has a half-life measured in milliseconds and can either become inactive by undergoing hydrolysis in the fluid-phase or form an ester or imidoester bond with a nearby reactive surface. The biochemical/biophysical properties of the reactive surface influence the efficiency of binding of nascent C3b to that particular surface. Previous studies from this laboratory have demonstrated that for human erythrocytes, C3b binds predominately to glycophorin-a by forming an ester bond with free hydroxyl groups of the carbohydrate moiety of the molecule (13). It seems likely, then, that the formation of GP,, induces conformational changes in the glycophorin-a constituent of the GP<,. complex such that its glycosyl residues are more readily available for interaction with the labile-binding site of C3b, thereby accounting for the greater efficiency of binding of fluid-phase activated C3b to CCAD erythrocytes (Fig. 3) . Alternatively (or in addition), the CoFBb complexes might have a greater affinity for CCAD erythrocytes, thereby accounting for the greater binding of nascent C3b as a result of activation closer to the cell surface. While there was no statistically significant quantitative difference in the binding of 125I-CoFBb complexes to CCAD erythrocytes compared with normals (data not shown), it is possible that the complexes have a higher affinity for these abnormal cells which is not defined by the methods employed for these binding studies (separating the bound from the unbound ligand by spinning the cells through a phthalate or mixture [5] ).
The erythrocytes of paroxysmal nocturnal hemoglobinuria (PNH) also bind more C3b than normal erythrocytes when complement is activated (3) , and this greater binding of C3b also appears to be related, at least in part, to an abnormality in glycophorin-a (13). However, PNH erythrocytes do not bind C3b more efficiently than normal erythrocytes (3). Rather, in this case, it appears that the abnormality in glycophorin-a modifies the enzyme substrate interactions of the cell-bound alternative pathway convertase such that the convertase has greater enzymatic activity when affixed to PNH erythrocytes (3) .
The biochemical composition of the surface upon which the complexes of the complement sequence are organized has been shown to greatly influence the activity of the constituent components of the complexes (13) . However, this appears to be the first report demonstrating that antibody and complement interactions with membrane glycoproteins can induce biophysical changes in the intrinsic properties of the membrane which modify subsequent interactions with complement.
Whether the C3b which is bound to GPc. is itself functionally aberrant and whether GP,>, formation modulates other abnormal interaction with complement remain to be determined.
All of the C3b which is bound to CCAD after fluid-phase activation is released by treatment with hydroxylamine (Fig.  4, lane 5) . This contrasts sharply with the situation involving the C3dg which is bound to CCAD erythrocytes under in vivo conditions. In this case, only a very minor portion of the bound molecules are released by treatment with hydroxylamine ( Fig. 2 B, lane 4) . This suggests that the C3b which becomes bound as a result of complement activation by cell-bound IgM cold agglutinin forms primarily hydroxylamine-insensitive imidoester bonds, while fluid-phase-activated C3b forms exclusively hydroxylamine-sensitive ester bonds. (Interestingly, C3b which is bound after activation by the membrane-associated C3 nephritic factor-stabilized alternative pathway convertase [using purified complement components] is predominately, though not exclusively, hydroxylamine sensitive [13] ). Apparently, then, interactions of the anti-I with its antigenic determinants mediate the biochemical events which favor imidoester bond formation between C3b and glycophorin-a. Alternatively (or in addition), C3b which is bound via ester bonds in vivo may be more readily lost from the cell surface during circulation. The differences in types of bonding of C3b to cell surfaces may be of physiological importance since we have previously demonstrated that factor H binding to EC3b is influenced by the mode of C3 activation employed to create the C3b-bearing erythrocytes (5) .
The erythrocytes of the four patients with CCAD have very low numbers of CR1 sites as determined by binding studies using a monoclonal antibody to CRI (Table II) . The presence of cell-bound C3b (up to 30,000 molecules/cell) does not reduce the number of CR1 sites per cell (data not shown); nor does the presence of cell-bound C3dg (Table IV) , and apparently neither does the process of C3b conversion to C3dg (Table IV) . Using this same antibody, we have noted low numbers of CR1 sites on the erythrocytes of patients with IgG-mediated warm antibody heinolytic anemia whose erythrocytes bear C3dg (18) . Thus, in the case of hemolytic anemias, low CR1 sites appear to be an epiphenomenon associated with the activation and fixation of C3 to the erythrocyte membrane surface. However, the reduction of CR1 sites does not occur under the in vitro conditions employed in the experiments whose results are depicted in Table IV . Perhaps, the interactions of erythrocytes bearing C3 fragments with elements of the reticuloendothelial system which possess complement receptors (22) (23) (24) (25) are required to reduce the numbers of erythrocyte CR1 sites.
The erythrocytes of CCAD are abnormally resistant to complement-mediated hemolysis by cold agglutinins (26, 27) . This phenomenon has been attributed to inhibition of binding of the lgM antibody to CCAD erythrocytes as a result of steric hinderance by incomplete complement complexes (26, 27) . The studies reported here suggest that alterations in the biochemical properties of intrinsic membrane glycoproteins by antibody and complement may also be important in pathophysiological manifestations of CCAD, particularly in relation to complement-mediated events.
